-
1
-
-
0036786670
-
Ten-year incidence of agerelated maculopathy and smoking and drinking: The Beaver Dam Eye Study
-
Klein R, Klein BE, Tomany SC, Moss SE. Ten-year incidence of agerelated maculopathy and smoking and drinking: The Beaver Dam Eye Study. Am J Epidemiol. 2002;156:589-98.
-
(2002)
Am J Epidemiol
, vol.156
, pp. 589-598
-
-
Klein, R.1
Klein, B.E.2
Tomany, S.C.3
Moss, S.E.4
-
3
-
-
0038708118
-
Age-related macular degeneration: Etiology, pathogenesis, and therapeutic strategies
-
DOI 10.1016/S0039-6257(03)00030-4
-
Ambati J, Ambati BK, Yoo SH, et al. Age-related macular degeneration: Etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol. 2003;48:257-93. (Pubitemid 36553096)
-
(2003)
Survey of Ophthalmology
, vol.48
, Issue.3
, pp. 257-293
-
-
Ambati, J.1
Ambati, B.K.2
Yoo, S.H.3
Ianchulev, S.4
Adamis, A.P.5
-
4
-
-
0026681119
-
Prevalence of age-related maculopathy: The Beaver Dam Eye Study
-
Klein R, Klein BEK, Linton KLP. Prevalence of age-related maculopathy: The Beaver Dam Eye Study. Ophthalmology. 1992;99:933-43.
-
(1992)
Ophthalmology
, vol.99
, pp. 933-943
-
-
Klein, R.1
Klein, B.E.K.2
Linton, K.L.P.3
-
5
-
-
0028843796
-
Prevalence of age-related maculopathy in Australia: The Blue Mountain Eye Study
-
Mitchell P, Smith W, Altebo K, Wang JJ. Prevalence of age-related maculopathy in Australia: The Blue Mountain Eye Study. Ophthalmology. 1995;102:1450-60.
-
(1995)
Ophthalmology
, vol.102
, pp. 1450-1460
-
-
Mitchell, P.1
Smith, W.2
Altebo, K.3
Wang, J.J.4
-
6
-
-
0028839002
-
The prevalence of agerelated maculopathy in the Rotterdam Study
-
Vingerling JR, Diclemans I, Hofman A, et al. The prevalence of agerelated maculopathy in the Rotterdam Study. Ophthalmology. 1995;102: 205-10.
-
(1995)
Ophthalmology
, vol.102
, pp. 205-210
-
-
Vingerling, J.R.1
Diclemans, I.2
Hofman, A.3
-
7
-
-
50249172959
-
Age-period-cohort effect on the incidence of age-related macular degeneration: The Beaver Dam Eye Study
-
Klein R, Knudtson MD, Lee KE, et al. Age-period-cohort effect on the incidence of age-related macular degeneration: The Beaver Dam Eye Study. Ophthalmology. 2008;115:1460-7.
-
(2008)
Ophthalmology
, vol.115
, pp. 1460-1467
-
-
Klein, R.1
Knudtson, M.D.2
Lee, K.E.3
-
9
-
-
0038010714
-
Progression of age-related macular degeneration: Association with body mass index, waist circumference, and waist-hip ratio
-
DOI 10.1001/archopht.121.6.785
-
Seddon JM, Cote J, Davis N, Rosner B. Progression of age-related macular degeneration: Association with body mass index, waist circumference, and waist-hip ratio. Arch Ophthalmol. 2003;121:785-92. (Pubitemid 36676214)
-
(2003)
Archives of Ophthalmology
, vol.121
, Issue.6
, pp. 785-792
-
-
Seddon, J.M.1
Cote, J.2
Davis, N.3
Rosner, B.4
-
10
-
-
55949093510
-
Changes in abdominal obesity and age-related macular degeneration: The Atherosclerosis Risk in Communities Study
-
Peeters A, Magliano DJ, Stevens J, et al. Changes in abdominal obesity and age-related macular degeneration: The Atherosclerosis Risk in Communities Study. Arch Ophthalmol. 2008;126:1554-60.
-
(2008)
Arch Ophthalmol
, vol.126
, pp. 1554-1560
-
-
Peeters, A.1
Magliano, D.J.2
Stevens, J.3
-
11
-
-
0029758899
-
A prospective study of cigarette smoking and age-related macular degeneration in women
-
DOI 10.1001/jama.276.14.1141
-
Seddon JM, Willett WC, Speizer FE, Hankinson SE. A prospective study of cigarette smoking and age-related macular degeneration in women. JAMA. 1996;276:1141-6. (Pubitemid 26329740)
-
(1996)
Journal of the American Medical Association
, vol.276
, Issue.14
, pp. 1141-1146
-
-
Seddon, J.M.1
Willett, W.C.2
Speizer, F.E.3
Hankinson, S.E.4
-
12
-
-
0029759549
-
A prospective study of cigarette smoking and risk of age-related macular degeneration in men
-
DOI 10.1001/jama.276.14.1147
-
Christen WG, Glynn RJ, Manson JE, et al. A prospective study of cigarette smoking and risk of age-related macular degeneration in men. JAMA. 1996;276:1147-51. (Pubitemid 26329741)
-
(1996)
Journal of the American Medical Association
, vol.276
, Issue.14
, pp. 1147-1151
-
-
Christen, W.G.1
Glynn, R.J.2
Manson, J.E.3
Ajani, U.A.4
Buring, J.E.5
-
13
-
-
33747185607
-
Associations between intermediate age-related macular degeneration and lutein and zeaxanthin in the Carotenoids in Age-Related Eye Disease Study (CAREDS): Ancillary study of the Women's Health Initiative
-
DOI 10.1001/archopht.124.8.1151
-
Moeller SM, Parekh N, Tinker L, et al. Associations between intermediate age-related macular degeneration and lutein and zeaxanthin in the Carotenoids in Age-related Eye Disease Study (CAREDS): Ancillary study of the Women's Health Initiative. Arch Ophthalmol. 2006;124: 1151-62. (Pubitemid 44232345)
-
(2006)
Archives of Ophthalmology
, vol.124
, Issue.8
, pp. 1151-1162
-
-
Moeller, S.M.1
Parekh, N.2
Tinker, L.3
Ritenbaugh, C.4
Blodi, B.5
Wallace, R.B.6
Mares, J.A.7
-
14
-
-
34548650913
-
The relationship of dietary carotenoid and vitamin A, E, and C intake with age-related macular degeneration in a case-control study: AREDS Report No. 22
-
Age-Related Eye Disease Study Research Group
-
Age-Related Eye Disease Study Research Group. The relationship of dietary carotenoid and vitamin A, E, and C intake with age-related macular degeneration in a case-control study: AREDS Report No. 22. Arch Ophthalmol. 2007;125:1225-32.
-
(2007)
Arch Ophthalmol
, vol.125
, pp. 1225-1232
-
-
-
15
-
-
45149132510
-
Dietary ω-3 fatty acid and fish intake in the primary prevention of age-related macular degeneration: A systematic review and meta-analysis
-
DOI 10.1001/archopht.126.6.826
-
Chong EW, Kreis AJ, Wong TY, et al. Dietary omega-3 fatty acid and fish intake in the primary prevention of age-related macular degeneration: A systematic review and meta-analysis. Arch Ophthalmol. 2008; 126:826-33. (Pubitemid 351831334)
-
(2008)
Archives of Ophthalmology
, vol.126
, Issue.6
, pp. 826-833
-
-
Chong, E.W.-T.1
Kreis, A.J.2
Wong, T.Y.3
Simpson, J.A.4
Guymer, R.H.5
-
16
-
-
0034800655
-
A randomized, placebo- controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS Report No. 8
-
Age-Related Eye Disease Study Research Group
-
Age-Related Eye Disease Study Research Group. A randomized, placebo- controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS Report No. 8. Arch Ophthalmol. 2001; 119:1417-36.
-
(2001)
Arch Ophthalmol
, vol.119
, pp. 1417-1436
-
-
-
17
-
-
0034677435
-
Age-related macular degeneration
-
DOI 10.1056/NEJM200002173420707
-
Fine SL, Berger JW, Maguire MG, Ho AC. Age-related macular degeneration. N Engl J Med. 2000;342:483-92. (Pubitemid 30100237)
-
(2000)
New England Journal of Medicine
, vol.342
, Issue.7
, pp. 483-492
-
-
Fine, S.L.1
Berger, J.W.2
Maguire, M.G.3
Ho, A.C.4
-
19
-
-
3242719404
-
Missense variations in the fibulin 5 gene and age-related macular degeneration
-
DOI 10.1056/NEJMoa040833
-
Stone EM, Braun TA, Russell SR, et al. Missense variations in the fibulin 5 gene and age-related macular degeneration. N Engl J Med. 2004;351: 346-53. (Pubitemid 38944403)
-
(2004)
New England Journal of Medicine
, vol.351
, Issue.4
, pp. 346-353
-
-
Stone, E.M.1
Braun, T.A.2
Russell, S.R.3
Kuehn, M.H.4
Lotery, A.J.5
Moore, P.A.6
Eastman, C.G.7
Casavant, T.L.8
Sheffield, V.C.9
-
20
-
-
67749120186
-
Meta-analysis of the association of the HTRA1 polymorphisms with the risk of age-related macular degeneration
-
Chen W, Xu W, Tao Q, et al. Meta-analysis of the association of the HTRA1 polymorphisms with the risk of age-related macular degeneration. Exp Eye Res. 2009;89:292-300.
-
(2009)
Exp Eye Res
, vol.89
, pp. 292-300
-
-
Chen, W.1
Xu, W.2
Tao, Q.3
-
21
-
-
33750300013
-
Association between apolipoprotein E polymorphisms and age-related macular degeneration: A HuGE review and meta-analysis
-
DOI 10.1093/aje/kwj279
-
Thakkinstian A, Bowe S, McEvoy M, et al. Association between apolipoprotein E polymorphisms and age-related macular degeneration: A HuGE review and meta-analysis. Am J Epidemiol. 2006;164:813-22. (Pubitemid 44627265)
-
(2006)
American Journal of Epidemiology
, vol.164
, Issue.9
, pp. 813-822
-
-
Thakkinstian, A.1
Bowe, S.2
McEvoy, M.3
Smith, W.4
Attia, J.5
-
22
-
-
33748752137
-
Systematic review and meta-analysis of the association between complementary factor H Y402H polymorphisms and age-related macular degeneration
-
DOI 10.1093/hmg/ddl220
-
Thakkinstian A, Han P, McEvoy M, et al. Systematic review and metaanalysis of the association between complement factor H Y402H polymorphisms and age-related macular degeneration. Hum Mol Genet. 2006;15:2784-90. (Pubitemid 44400405)
-
(2006)
Human Molecular Genetics
, vol.15
, Issue.18
, pp. 2784-2790
-
-
Thakkinstian, A.1
Han, P.2
McEvoy, M.3
Smith, W.4
Hoh, J.5
Magnusson, K.6
Zhang, K.7
Attia, J.8
-
23
-
-
36549016602
-
Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab
-
DOI 10.1016/j.ophtha.2007.09.008, PII S0161642007010263
-
Brantley MA Jr, Fang AM, King JM, et al. Association of complement factor H and LOC387715 genotypes with response of exudative agerelated macular degeneration to intravitreal bevacizumab. Ophthalmology. 2007;114:2168-73. (Pubitemid 350181136)
-
(2007)
Ophthalmology
, vol.114
, Issue.12
, pp. 2168-2173
-
-
Brantley Jr., M.A.1
Fang, A.M.2
King, J.M.3
Tewari, A.4
Kymes, S.M.5
Shiels, A.6
-
25
-
-
0023224438
-
Pathophysiology of age-related macular degeneration
-
DOI 10.1016/0039-6257(87)90115-9
-
Young RW. Pathophysiology of age-related macular degeneration. Surv Ophthalmol. 1987;31:291-306. (Pubitemid 17076515)
-
(1987)
Survey of Ophthalmology
, vol.31
, Issue.5
, pp. 291-306
-
-
Young, R.W.1
-
27
-
-
39049142223
-
Pegaptanib sodium for the treatment of age-related macular degeneration
-
DOI 10.1517/14656566.9.3.499
-
Apte RS. Pegaptanib sodium for the treatment of age-related macular degeneration. Expert Opin Pharmacother. 2008;9:499-508. (Pubitemid 351291794)
-
(2008)
Expert Opinion on Pharmacotherapy
, vol.9
, Issue.3
, pp. 499-508
-
-
Apte, R.S.1
-
28
-
-
20044375603
-
Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro
-
DOI 10.1007/s10456-004-8272-2
-
Wang Y, Fei D, Vanderlaan M, Song A. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis. 2004; 7:335-45 (Pubitemid 40767935)
-
(2004)
Angiogenesis
, vol.7
, Issue.4
, pp. 335-345
-
-
Wang, Y.1
Fei, D.2
Vanderlaan, M.3
Song, A.4
-
29
-
-
33749632278
-
Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration
-
DOI 10.1097/01.iae.0000242842.14624.e7, PII 0000698220061000000002
-
Ferrara N, Damico L, Shams N, et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006; 26:859-70. (Pubitemid 44547437)
-
(2006)
Retina
, vol.26
, Issue.8
, pp. 859-870
-
-
Ferrara, N.1
Damico, L.2
Shams, N.3
Lowman, H.4
Kim, R.5
-
30
-
-
35148885811
-
Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo
-
DOI 10.1016/j.exer.2007.05.008, PII S0014483507001534
-
Lowe J, Araujo J, Yang J, et al. Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo. Exp Eye Res. 2007;85:425-30. (Pubitemid 47542265)
-
(2007)
Experimental Eye Research
, vol.85
, Issue.4
, pp. 425-430
-
-
Lowe, J.1
Araujo, J.2
Yang, J.3
Reich, M.4
Oldendorp, A.5
Shiu, V.6
Quarmby, V.7
Lowman, H.8
Lien, S.9
Gaudreault, J.10
Maia, M.11
-
31
-
-
52949113486
-
Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization
-
Zhu Q, Ziemssen F, Henke-Fahle S, et al. Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization. Ophthalmology. 2008;115):1750-5.
-
(2008)
Ophthalmology
, Issue.115
, pp. 1750-1755
-
-
Zhu, Q.1
Ziemssen, F.2
Henke-Fahle, S.3
-
32
-
-
36549039554
-
Pharmacokinetics of Intravitreal Ranibizumab (Lucentis)
-
DOI 10.1016/j.ophtha.2007.09.012, PII S0161642007010305
-
Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology. 2007;114:2179-82. (Pubitemid 350181137)
-
(2007)
Ophthalmology
, vol.114
, Issue.12
, pp. 2179-2182
-
-
Bakri, S.J.1
Snyder, M.R.2
Reid, J.M.3
Pulido, J.S.4
Ezzat, M.K.5
Singh, R.J.6
-
33
-
-
51649109046
-
Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans
-
Krohne TU, Eter N, Holz FG, Meyer CH. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol. 2008;146:508-12.
-
(2008)
Am J Ophthalmol
, vol.146
, pp. 508-512
-
-
Krohne, T.U.1
Eter, N.2
Holz, F.G.3
Meyer, C.H.4
-
34
-
-
34347213068
-
Penetration of bevacizumab through the retina after intravitreal injection in the monkey
-
DOI 10.1167/iovs.06-1171
-
Heiduschka P, Fietz H, Hofmeister S, et al. Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci. 2007;48:2814-23. (Pubitemid 351261238)
-
(2007)
Investigative Ophthalmology and Visual Science
, vol.48
, Issue.6
, pp. 2814-2823
-
-
Heiduschka, P.1
Fietz, H.2
Hofmeister, S.3
Schultheiss, S.4
Mack, A.F.5
Peters, S.6
Ziemssen, F.7
Niggemann, B.8
Julien, S.9
Bartz-Schmidt, K.U.10
Schraermeyer, U.11
-
35
-
-
36749003833
-
Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits
-
DOI 10.1097/IAE.0b013e318134eecd, PII 0000698220071100000018
-
Gaudreault J, Fei D, Beyer JC, et al. Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits. Retina. 2007;27:1260-6. (Pubitemid 350211535)
-
(2007)
Retina
, vol.27
, Issue.9
, pp. 1260-1266
-
-
Gaudreault, J.1
Fei, D.2
Beyer, J.C.3
Ryan, A.4
Rangell, L.5
Shiu, V.6
Damico, L.A.7
-
36
-
-
33749445317
-
Ranibizumab for neovascular age-related macular degeneration
-
DOI 10.1056/NEJMoa054481
-
Rosenfeld PJ, Brown DM, Heier JS, et al., MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419-31. (Pubitemid 44511557)
-
(2006)
New England Journal of Medicine
, vol.355
, Issue.14
, pp. 1419-1431
-
-
Rosenfeld, P.J.1
Brown, D.M.2
Heier, J.S.3
Boyer, D.S.4
Kaiser, P.K.5
Chung, C.Y.6
Kim, R.Y.7
-
37
-
-
57949094834
-
Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study
-
ANCHOR Study Group
-
Brown DM, Michels M, Kaiser PK, et al., ANCHOR Study Group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology. 2009;116:57-65.
-
(2009)
Ophthalmology
, vol.116
, pp. 57-65
-
-
Brown, D.M.1
Michels, M.2
Kaiser, P.K.3
-
38
-
-
38349172455
-
Randomized, doublemasked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1
-
Regillo CD, Brown DM, Abraham P, et al. Randomized, doublemasked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol. 2008; 145:239-48.
-
(2008)
Am J Ophthalmol
, vol.145
, pp. 239-248
-
-
Regillo, C.D.1
Brown, D.M.2
Abraham, P.3
-
40
-
-
69249222585
-
A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration
-
Boyer DS, Heier JS, Brown DM, et al. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology. 2009;116:1731-9.
-
(2009)
Ophthalmology
, vol.116
, pp. 1731-1739
-
-
Boyer, D.S.1
Heier, J.S.2
Brown, D.M.3
-
41
-
-
57849120440
-
Ranibizumab in patients with subfoveal choroidal neovascularization secondary to agerelated macular degeneration: Interim results from the Sustain Trial
-
SUSTAIN Study Group. E-abstract 273
-
Meyer CH, Eter N, Holz FG, SUSTAIN Study Group. Ranibizumab in patients with subfoveal choroidal neovascularization secondary to agerelated macular degeneration: Interim results from the Sustain Trial. Invest Ophthalmol Vis Sci. 2008;49:E-abstract 273.
-
(2008)
Invest Ophthalmol Vis Sci
, vol.49
-
-
Meyer, C.H.1
Eter, N.2
Holz, F.G.3
-
42
-
-
33947403618
-
An optical coherence tomography- guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration
-
Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography- guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007;143:566-83.
-
(2007)
Am J Ophthalmol
, vol.143
, pp. 566-583
-
-
Fung, A.E.1
Lalwani, G.A.2
Rosenfeld, P.J.3
-
43
-
-
33750314559
-
Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: Year 1 results of the FOCUS study
-
DOI 10.1001/archopht.124.11.1532
-
Heier JS, Boyer DS, Ciulla TA, et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: Year 1 results of the FOCUS study. Arch Ophthalmol. 2006;124:1532-42. (Pubitemid 44748725)
-
(2006)
Archives of Ophthalmology
, vol.124
, Issue.11
, pp. 1532-1542
-
-
Heier, J.S.1
Boyer, D.S.2
Ciulla, T.A.3
Ferrone, P.J.4
Jumper, J.M.5
Gentile, R.C.6
Kotlovker, D.7
Chung, C.Y.8
Kim, R.Y.9
-
46
-
-
80053354753
-
Verteporfin PDT and ranibizumab combination therapy for symptomatic macular polypoidal choroidal vasculopathy (PCV): EVEREST results
-
The EVEREST study group
-
Lai TY, The EVEREST study group. Verteporfin PDT and ranibizumab combination therapy for symptomatic macular polypoidal choroidal vasculopathy (PCV): EVEREST results. Invest Ophthalmol Vis Sci. 2010;51(suppl):S2228.
-
(2010)
Invest Ophthalmol Vis Sci
, vol.51
, Issue.SUPPL.
-
-
Lai, T.Y.1
-
47
-
-
56949108327
-
A systematic review on the effect of bevacizumab in exudative age-related macular degeneration
-
Schouten JS, La Heij EC, Webers CA, et al. A systematic review on the effect of bevacizumab in exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2009;247:1-11.
-
(2009)
Graefes Arch Clin Exp Ophthalmol
, vol.247
, pp. 1-11
-
-
Schouten, J.S.1
La Heij, E.C.2
Webers, C.A.3
-
48
-
-
67649996349
-
Off-label use of bevacizumab for the treatment of age-related macular degeneration: What is the evidence?
-
Ziemssen F, Grisanti S, Bartz-Schmidt KU, SpitzerMS. Off-label use of bevacizumab for the treatment of age-related macular degeneration: What is the evidence? Drugs Aging. 2009;26:295-320.
-
(2009)
Drugs Aging
, vol.26
, pp. 295-320
-
-
Ziemssen, F.1
Grisanti, S.2
Bartz-Schmidt, K.U.3
Spitzer, M.S.4
-
49
-
-
77951272899
-
Intravitreal bevacizumab (Avastin) vs. ranibizumab (Lucentis) for the treatment of age-related macular degeneration: A systematic review
-
Schmucker C, Ehlken C, Hansen LL, et al. Intravitreal bevacizumab (Avastin) vs. ranibizumab (Lucentis) for the treatment of age-related macular degeneration: A systematic review. Curr Opin Ophthalmol. 2010;21:218-26.
-
(2010)
Curr Opin Ophthalmol
, vol.21
, pp. 218-226
-
-
Schmucker, C.1
Ehlken, C.2
Hansen, L.L.3
-
50
-
-
79956218863
-
Ranibizumab and bevacizumab for neovascular age-related macular degeneration
-
CATT Research Group
-
CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364:1897-908.
-
(2011)
N Engl J Med.
, vol.364
, pp. 1897-1908
-
-
-
51
-
-
14744267295
-
Impact of lesion size on photodynamic therapy with verteporfin of predominantly classic lesions in age related macular degeneration
-
DOI 10.1136/bjo.2004.050997
-
Arias L, Pujol O, Berniell J, et al. Impact of lesion size on photodynamic therapy with verteporfin of predominantly classic lesions in age-related macular degeneration. Br J Ophthalmol. 2005;89:312-5. (Pubitemid 40327615)
-
(2005)
British Journal of Ophthalmology
, vol.89
, Issue.3
, pp. 312-315
-
-
Arias, L.1
Pujol, O.2
Berniell, J.3
Rubio, M.4
Roca, G.5
Castillo, L.6
Acebes, E.7
-
52
-
-
14944378549
-
Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: Update
-
Verteporfin Roundtable Participants
-
Verteporfin Roundtable Participants. Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: Update. Retina. 2005;25:119-34.
-
(2005)
Retina
, vol.25
, pp. 119-134
-
-
-
53
-
-
34248174811
-
Use of optical coherence tomography, fluorescein angiography and indocyanine green angiography in a screening clinic for wet age-related macular degeneration
-
DOI 10.1136/bjo.2006.108043
-
Talks J, Koshy Z, Chatzinikolas K. Use of optical coherence tomography, fluorescein angiography and indocyanine green angiography in a screening clinic for wet age-related macular degeneration. Br J Ophthalmol. 2007;91:600-1. (Pubitemid 46716524)
-
(2007)
British Journal of Ophthalmology
, vol.91
, Issue.5
, pp. 600-601
-
-
Talks, J.1
Koshy, Z.2
Chatzinikolas, K.3
-
54
-
-
70549098650
-
Optical coherence tomography in neovascular age related macular degeneration compared to fluorescein angiography and visual acuity
-
Henschel A, Spital G, Lommatzsch A, Pauleikhoff D. Optical coherence tomography in neovascular age related macular degeneration compared to fluorescein angiography and visual acuity. Eur J Ophthalmol. 2009; 19:831-5.
-
(2009)
Eur J Ophthalmol
, vol.19
, pp. 831-835
-
-
Henschel, A.1
Spital, G.2
Lommatzsch, A.3
Pauleikhoff, D.4
-
55
-
-
65549113426
-
Safety and efficacy of intravitreal anti-VEGF injections for age-related macular degeneration
-
Jeganathan VS, Verma N. Safety and efficacy of intravitreal anti-VEGF injections for age-related macular degeneration. Curr Opin Ophthalmol. 2009;20:223-5.
-
(2009)
Curr Opin Ophthalmol
, vol.20
, pp. 223-225
-
-
Jeganathan, V.S.1
Verma, N.2
-
57
-
-
74549137478
-
Ranibizumab (Lucentis) in neovascular age-related macular degeneration: Evidence from clinical trials
-
Mitchell P, Korobelnik JF, Lanzetta P, et al. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: Evidence from clinical trials. Br J Ophthalmol. 2010;94:2-13.
-
(2010)
Br J Ophthalmol
, vol.94
, pp. 2-13
-
-
Mitchell, P.1
Korobelnik, J.F.2
Lanzetta, P.3
-
58
-
-
77953299956
-
Identifying systemic safety signals following intravitreal bevacizumab: Systematic review of the literature and the Canadian Adverse Drug Reaction Database
-
Micieli JA, Micieli A, Smith AF. Identifying systemic safety signals following intravitreal bevacizumab: Systematic review of the literature and the Canadian Adverse Drug Reaction Database. Can J Ophthalmol. 2010;45:231-8.
-
(2010)
Can J Ophthalmol
, vol.45
, pp. 231-238
-
-
Micieli, J.A.1
Micieli, A.2
Smith, A.F.3
-
59
-
-
84899774968
-
-
CATT: Lucentis-Avastin Trial. Accessed October 27, 2010
-
CATT: Lucentis-Avastin Trial. Manual of Procedures. Available online: www.med.upenn.edu/cpob/studies/documents/CATTManualof ProceduresMay2010-000.pdf. Accessed October 27, 2010.
-
Manual of Procedures
-
-
-
60
-
-
77953358874
-
High-molecular-weight aggregates in repackaged bevacizumab
-
Kahook MY, Liu L, Ruzycki P, et al. High-molecular-weight aggregates in repackaged bevacizumab. Retina. 2010;30:887-92.
-
(2010)
Retina
, vol.30
, pp. 887-892
-
-
Kahook, M.Y.1
Liu, L.2
Ruzycki, P.3
-
61
-
-
64849085452
-
Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin)
-
Georgopoulos M, Polak K, Prager F, et al. Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin). Br J Ophthalmol. 2009;93:457-62.
-
(2009)
Br J Ophthalmol
, vol.93
, pp. 457-462
-
-
Georgopoulos, M.1
Polak, K.2
Prager, F.3
-
62
-
-
33750296920
-
The International Intravitreal Bevacizumab Safety Survey: Using the internet to assess drug safety worldwide
-
DOI 10.1136/bjo.2006.099598
-
Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: Using the internet to assess drug safety worldwide. Br J Ophthalmol. 2006;90:1344-9. (Pubitemid 44702055)
-
(2006)
British Journal of Ophthalmology
, vol.90
, Issue.11
, pp. 1344-1349
-
-
Fung, A.E.1
Rosenfeld, P.J.2
Reichel, E.3
-
63
-
-
36448993366
-
Twelve-month safety of intravitreal injections of bevacizumab (Avastin®): Results of the pan-american collaborative retina study group (PACORES)
-
DOI 10.1007/s00417-007-0660-z
-
Wu L, Martínez-Castellanos MA, Quiroz-Mercado H, et al. Twelvemonth safety of intravitreal injections of bevacizumab (Avastin): Results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol. 2008;246:81-7. (Pubitemid 350167096)
-
(2008)
Graefe's Archive for Clinical and Experimental Ophthalmology
, vol.246
, Issue.1
, pp. 81-87
-
-
Wu, L.1
Martinez-Castellanos, M.A.2
Quiroz-Mercado, H.3
Arevalo, J.F.4
Berrocal, M.H.5
Farah, M.E.6
Maia, M.7
Roca, J.A.8
Rodriguez, F.J.9
-
64
-
-
77953300103
-
Incidence and characteristics of acute intraocular inflammation after intravitreal injection of bevacizumab: A retrospective cohort study
-
Johnson D, Hollands H, Hollands S, Sharma S. Incidence and characteristics of acute intraocular inflammation after intravitreal injection of bevacizumab: A retrospective cohort study. Can J Ophthalmol. 2010;45:239-42.
-
(2010)
Can J Ophthalmol
, vol.45
, pp. 239-242
-
-
Johnson, D.1
Hollands, H.2
Hollands, S.3
Sharma, S.4
-
65
-
-
77958001574
-
Risks of mortality,myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration
-
CurtisLH,HammillBG,SchulmanKA,CousinsSW.Risks of mortality,myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol. 2010;128:1273-9.
-
(2010)
Arch Ophthalmol
, vol.128
, pp. 1273-1279
-
-
Curtis, L.H.1
Hammill, B.G.2
Schulman, K.A.3
Cousins, S.W.4
-
67
-
-
77958001574
-
Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration
-
Curtis LH, Hammill BG, Schulman KA, Cousins SW. Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol. 2010;128:1273-9.
-
(2010)
Arch Ophthalmol
, vol.128
, pp. 1273-1279
-
-
Curtis, L.H.1
Hammill, B.G.2
Schulman, K.A.3
Cousins, S.W.4
-
70
-
-
38149099226
-
Burden of illness of neovascular age-related macular degeneration in Canada
-
Cruess A, Zlateva G, Xu X, Rochon S. Burden of illness of neovascular age-related macular degeneration in Canada. Can J Ophthalmol. 2007; 42:836-43.
-
(2007)
Can J Ophthalmol
, vol.42
, pp. 836-843
-
-
Cruess, A.1
Zlateva, G.2
Xu, X.3
Rochon, S.4
-
71
-
-
77953310762
-
Pharmacologic management of neovascular age-related macular degeneration: Systematic review of economic evidence and primary economic evaluation
-
Hodge W, Brown A, Kymes S, et al. Pharmacologic management of neovascular age-related macular degeneration: Systematic review of economic evidence and primary economic evaluation. Can J Ophthalmol. 2010;45:223-30.
-
(2010)
Can J Ophthalmol
, vol.45
, pp. 223-230
-
-
Hodge, W.1
Brown, A.2
Kymes, S.3
-
72
-
-
0026575912
-
How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations
-
Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ. 1992;146:473-81.
-
(1992)
CMAJ
, vol.146
, pp. 473-481
-
-
Laupacis, A.1
Feeny, D.2
Detsky, A.S.3
Tugwell, P.X.4
-
74
-
-
1242342156
-
Health care economic analyses
-
Brown GC, BrownMM,Sharma S, et al. Health care economic analyses. Retina. 2004;24:139-46.
-
(2004)
Retina
, vol.24
, pp. 139-146
-
-
Brown, G.C.1
Brownmmsharma, S.2
-
75
-
-
42249105678
-
Cost-utility analysis of telemedicine and ophthalmoscopy for retinopathy of prematurity management
-
DOI 10.1001/archopht.126.4.493
-
Jackson KM, Scott KE, Graff Zivin J, et al. Cost-utility analysis of telemedicine and ophthalmoscopy for retinopathy of prematurity management. Arch Ophthalmol. 2008;126:493-9. (Pubitemid 351549840)
-
(2008)
Archives of Ophthalmology
, vol.126
, Issue.4
, pp. 493-499
-
-
Jackson, K.M.1
Scott, K.E.2
Graff Zivin, J.3
Bateman, D.A.4
Flynn, J.T.5
Keenan, J.D.6
Chiang, M.F.7
-
76
-
-
33947160622
-
Ophthalmology human resource projections: Are we heading for a crisis in the next 15 years?
-
DOI 10.1139/I06-115
-
Bellan L, Buske L. Ophthalmology human resource projections: Are we heading for a crisis in the next 15 years? Can J Ophthalmol. 2007;42:34-8. (Pubitemid 46408891)
-
(2007)
Canadian Journal of Ophthalmology
, vol.42
, Issue.1
, pp. 34-38
-
-
Bellan, L.1
Buske, L.2
-
77
-
-
70349449765
-
The treatment of wet AMD in Canada: Access to therapy (policy review)
-
Cruess A, Maberley D, Wong D, Chen J. The treatment of wet AMD in Canada: access to therapy (policy review). Can J Ophthalmol. 2009;44: 548-56.
-
(2009)
Can J Ophthalmol
, vol.44
, pp. 548-556
-
-
Cruess, A.1
Maberley, D.2
Wong, D.3
Chen, J.4
-
78
-
-
84899783898
-
-
Accessed September 6, 2010
-
The Facts on British Columbia's Wet AMD Program. Available online: www.gov.bc.ca/fortherecord/wetamd/wt-healthcare.html?src-/healthcare/ wt-healthcare.html. Accessed September 6, 2010.
-
The Facts on British Columbia's Wet AMD Program
-
-
-
79
-
-
43749096100
-
Neovascular age-related macular degeneration: Potential therapies
-
DOI 10.2165/00003495-200868080-00002
-
Chappelow AV, Kaiser PK. Neovascular age-related macular degeneration: Potential therapies. Drugs. 2008;68:1029-36. (Pubitemid 351693673)
-
(2008)
Drugs
, vol.68
, Issue.8
, pp. 1029-1036
-
-
Chappelow, A.V.1
Kaiser, P.K.2
-
80
-
-
78449283380
-
Current and emerging therapies for the treatment of age-related macular degeneration
-
Emerson MV, Lauer AK. Current and emerging therapies for the treatment of age-related macular degeneration. Clin Ophthalmol. 2008;2: 377-88.
-
(2008)
Clin Ophthalmol
, vol.2
, pp. 377-388
-
-
Emerson, M.V.1
Lauer, A.K.2
-
82
-
-
70350757650
-
A Phase i study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration
-
Nguyen QD, Shah SM, Browning DJ, et al. A Phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration. Ophthalmology. 2009;116: 2141-8.
-
(2009)
Ophthalmology
, vol.116
, pp. 2141-2148
-
-
Nguyen, Q.D.1
Shah, S.M.2
Browning, D.J.3
-
83
-
-
84899775941
-
VEGF trap-eye noninferior to ranibizumab in two phase 3 trials
-
Accessed January 12, 2010
-
VEGF trap-eye noninferior to ranibizumab in two phase 3 trials. Retina Today. 2010. Available online: www.advancedocularcare.bmctoday.net/retinatoday/ 2010/12/article.asp?f-vegf-trap-eye-noninferior-toranibizumab- in-two-phase-3-trials. Accessed January 12, 2010.
-
(2010)
Retina Today
-
-
|